Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in developing adult stem cell therapies for neurodegenerative disorders, such as amyotrophic lateral sclerosis (ALS), Parkinsons disease, and multiple sclerosis. It holds rights to develop and commercialize its NurOwn technology through a worldwide licensing agreement with Ramot, the technology transfer company of the Tel Aviv University.
BCLI's NurOwn technology, an autologous adult stem cell therapy technology that differentiates bone marrow-derived mesenchymal stem cells into specialized neuron-supporting cells. It also has agreements with Hadasit Medical Research Services and Development Ltd. to conduct its ALS clinical trials at the Hadassah Medical Center.
Brainstorm Cell Therapy was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. BCLI was founded in 2000 and is based in New York, New York.
May 17, 2024
RegMed Investors (RMi) Closing Bell: sector headwinds caused small gains and big losses
May 15, 2024
RegMed Investors (RMi) Closing Bell: stayed level re a.m. title
May 15, 2024
RegMed Investors (RMi) - Q1/24 Cell and Gene Therapy Earnings Scorecard Results
May 15, 2024
RegMed Investors’ (RMi) pre-open: multiple data releases levels indexes and sector’s share pricing?
May 14, 2024
RegMed Investors (RMi) Closing Bell: always waiting with inflation data trepidation
May 10, 2024
RegMed Investors (RMi) Closing Bell: racing to anther bottom
May 9, 2024
RegMed Investors (RMi) Closing Bell: elasticity
May 8, 2024
RegMed Investors (RMi) Closing Bell: slam, bam, no thank you ma’am
May 3, 2024
RegMed Investors (RMi) Closing Bell: green on the sector screen, with a trickle starting to the downside
35 companies, 1 interpreter!
Insight, foresight and recommendation
Brainstorm Cell Therapeutics (BCLI) – January '18 openaed at $3.65, dropping in February to $3.45 and continuing to drop to $3.10 on 2/12 and $3.19 on 2/16. Even with their on-going trial, I have a problem with theor corporate transparency ... tey revolve on news and the pricing falls back ...
holdMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors